Previous Article | Next Article ![]()
Journal of Virology, April 2001, p. 3335-3342, Vol. 75, No. 7
Crucell Holland B.V., 2301 CA
Leiden,1 and Gaubius Laboratory TNO-PG, 2301 CE
Leiden,2 The Netherlands
Received 18 October 2000/Accepted 24 December 2000
To identify improved adenovirus vectors for
cardiovascular gene therapy, a library of adenovirus vectors based on
adenovirus serotype 5 (Ad5) but carrying fiber molecules of other human
serotypes, was generated. This library was tested for efficiency of
infection of human primary vascular endothelial cells (ECs) and smooth
muscle cells (SMCs). Based on luciferase, LacZ, or green fluorescent protein (GFP) marker gene expression, several fiber chimeric vectors were identified that displayed improved infection of these cell types.
One of the viruses that performed particularly well is an Ad5 carrying
the fiber of Ad16 (Ad5.Fib16), a subgroup B virus. This virus showed,
on average, 8- and 64-fold-increased luciferase activities on umbilical
vein ECs and SMCs, respectively, compared to the parent vector. GFP and
lacZ markers showed that approximately 3-fold (ECs) and
10-fold (SMCs) more cells were transduced. Experiments performed with
both cultured SMCs and organ cultures derived from different vascular
origins (saphenous vein, iliac artery, left interior mammary artery,
and aorta) and from different species demonstrated that Ad5.Fib16
consistently displays improved infection in primates (humans and rhesus
monkeys). SMCs of the same vessels of rodents and pigs were less
infectable with Ad5.Fib16 than with Ad5. This suggests that either the
receptor for human Ad16 is not conserved between different species or
that differences in the expression levels of the putative receptor
exist. In conclusion, our results show that an Ad5-based virus carrying
the fiber of Ad16 is a potent vector for the transduction of primate
cardiovascular cells and tissues.
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.7.3335-3342.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Improved Adenovirus Vectors for Infection of Cardiovascular
Tissues
*
Corresponding author. Mailing address: Crucell B.V.,
P.O. Box 2048, 2301 CA Leiden, The Netherlands. Phone: 3171-5248726. Fax: 3171-5248702. E-mail: m.havenga{at}crucell.com.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|